|Date||Product(s)||Safety Issue and Web Address|
|May 23, 2007||Gadolinium-Containing Contrast Agents [ Magnevist (gadopentate dimeglumine), Omniscan (gadodiamide), OptiMARK (gadoversetamide), MultiHance (gadobenate dimeglumine), and Prohance (gadoteridol) ]||Reports of nephrogenic systemic fibrosis (NSF)|
|May 21, 2007||Avandia, Avandemet, and Avandaryl (rosiglitazone maleate)||Pooled analysis of controlled clinical trials describing increased risks of heart attack and heart-related deaths|
|March 30, 2007||Zelnorm1 (tegaserod maleate)||Increased risk of heart attack, stroke and worsening heart chest pain|
|March 29, 2007||Permax2 (pergolide mesylate)||Increased risk of heart valve damage|
|March 16, 2007||Zyvox (linezolid)||Increased risk of death when used for intravascular catheter-related infections where there is a gram negative or no organism at time of study entry|
|March 9, 2007||Erythropoiesis Stimulating Agents [ Aranesp (darbepoetin alfa), Epogen (epoetin alfa), Procrit (epoetin alfa) ]||Increased risk of death, non-fatal heart attacks, strokes, heart failure, blood clots, and tumor progression|
|March 9, 2007||Actimmune (Interferon gamma-1b)||Early termination of clinical trial evaluating Actimmune for treatment of idiopathic pulmonary fibrosis (IPF) due to lack of benefit|
|February 21, 2007||Xolair (omalizumab)||Reports of delayed anaphylaxis|
|February 9, 2007||Topical Anesthetic Creams||Reports of life-threatening adverse events, such as an irregular heartbeat, seizures, and death|
- Withdrawn from marketing March 30, 2007.
- Withdrawn from marketing March 29, 2007.